G-NiiB Immunity+ enhance vaccines safety & efficacy

2021-03-31

Malaysia sees a spike in coronavirus cases in recent days. While herd immunity via mass scale vaccination is deemed to be the long-term solutions, there are continuous concern of individual on receiving vaccination. While seniors are believed to be the most vulnerable to coronavirus and potentially face a higher risk of severe illness once infected, the vaccine safety and possible side effects are the key concerns stopping them from getting vaccinated. Similarly, such concerns are found in various age groups.

G-NiiB “Immunity+”, a novel microbiome immunity formula developed by the Faculty of Medicine at The Chinese University of Hong Kong (CUHK Medicine), shows initial effectiveness in the suppression of inflammatory response associated with unwanted adverse events after vaccination. The related preliminary study showed the modulation of gut microbiota helps enhance safety and efficacy of the COVID-19 vaccine.

Recently, CUHK Medicine uncovered a link between the gut microbiome and COVID-19. Gut microbiota regulate our immune system and protect us against invasion from pathogens, while the vaccine triggers the immune system to develop antibodies and memory cells to protect against future infections. 

A preliminary study was conducted in the laboratory at CUHK Medicine to collect blood samples from individuals who had received COVID-19 vaccinations. Results showed that a beneficial bacteria consortium developed by CUHK Medicine is effective in reducing inflammatory cytokines and enhancing antibody level. Subjects who had taken the microbiome immunity formula (i.e. G-NiiB “Immunity+”) showed up to 80% lower concentration of inflammatory cytokine and a 1.5-fold higher proportion of B cell -- a blood cell that produces antibodies -- in their blood compared with a control group. “It is important for people to improve their gut microbiota to optimize the safety and efficacy of COVID-19 vaccines, which is especially crucial for the elderly, patients with obesity, diabetes or other chronic diseases,” said Professor Francis KL CHAN, Dean of Medicine and Director of the Centre for Gut Microbiota Research at CUHK.

G-NiiB ‘Immunity +’ is a unique microbiome immunity formula containing live freeze-dried ‘good’ bacteria with patented microencapsulation technology from Italy, and heat-resistant prebiotics to replenish beneficial microbes in the human gut. Using our proprietary database of over 10,000 subjects, big data analysis and machine learning algorithms, G-NiiB Immunity+ was formulated with an optimized 3+3 best ratio of live good bacteria and prebiotics to provide the BEST result and achieve our health goal.

G-NiiB has obtained exclusive patent* licensing from the Chinese University of Hong Kong. G-NiiB is a trademark of GenieBiome, a leading microbiome biotechnology start-up founded by professors from The Chinese University of Hong Kong.

*Patent-pending

~~Order Now~~

Delivery in Singapore: bit.ly/Lazada_SG_EN
Delivery in Malaysia: bit.ly/Lazada_MY_EN